Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
| ▸ | EML4 | Q9HC35 | 3/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.33 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | ETV6 | P41212 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944172 | 0.97 | TBK1 (0.39) | TBK1IKBKECCNCCDK8SYK | |
| Formic Acid SCHEMBL30206367 | 0.95 | IKBKE (0.43) | TBK1IKBKESYKMELKEML4 | |
| SCHEMBL30205589 | 0.92 | IKBKE (0.46) | TBK1IKBKESYKMELKEML4 | |
| SCHEMBL24943840 | 0.92 | IKBKE (0.46) | TBK1IKBKESYKMELKEML4 | |
| SCHEMBL24944183 | 0.90 | SYK (0.44) | CCNCCDK8SYKEML4ALK | |
| SCHEMBL30205579 | 0.90 | SYK (0.44) | CCNCCDK8SYKEML4ALK | |
| Formic Acid SCHEMBL30205519 | 0.90 | EML4 (0.34) | TBK1IKBKECCNCCDK8SYK | |
| Formic Acid SCHEMBL29173283 | 0.90 | EML4 (0.34) | TBK1IKBKECCNCCDK8SYK | |
| Formic Acid SCHEMBL30205526 | 0.90 | EML4 (0.34) | TBK1IKBKECCNCCDK8SYK | |
| Formic Acid SCHEMBL31195388 | 0.90 | IKBKE (0.34) | TBK1IKBKECCNCCDK8SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | claimed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | claimed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | claimed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | TBK1 1990/4885IKBKE 223/4885CCNC 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.